BackCancer Genetics Overview

Cancer Genetics Long Term Debt

Cancer Genetics's long-term debt is $0.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer average / median

Loading

Cancer Genetics Long Term Debt History

Loading

Cancer Genetics vs. peers: Long Term Debt Comparison

Loading

Cancer Genetics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Cancer Genetics (CGIX) FAQ

Cancer Genetics (CGIX) currently reports a long-term debt of $0 as of December 2020. Use the charts on this page to explore Cancer Genetics's long-term debt history and peer comparisons.

Cancer Genetics reported $0 in long-term debt as of December 2020. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cancer Genetics, and consider following CGIX for alerts when major investors trade the stock.

Cancer Genetics is classified in the Healthcare sector. On long-term debt, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CGIX with unrelated industries.